Siva Rama Prasad Kambhampati

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Anthony W. Tolcher, Jordan Berlin, Jan Cosaert et al. · Cancer Chemotherapy and Pharmacology · 2017 · 101 citations · Full text

Pharmacy, Immunology, Oncology +12

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

Muhammad Wasif Saif, James A. Knost, E. Gabriela Chiorean et al. · Cancer Chemotherapy and Pharmacology · 2016 · 75 citations

Medicine, Immunology, Oncology +16

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

Miranda A. Moore, Sanjeev Gill, Timothy R. Asmis et al. · Annals of Oncology · 2016 · 37 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

Danny N. Khalil, Michael A. Postow, Nageatte Ibrahim et al. · Clinical Cancer Research · 2016 · 30 citations · Full text

Medicine, Cancer Biology, Oncology +17

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors

Patricia LoRusso, Mrinal M. Gounder, Shadia I. Jalal et al. · Investigational New Drugs · 2017 · 22 citations · Full text

Medicine, Oncology, Pharmacology +12